Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa

International Journal of Infectious Diseases

Volumn 13, Issue 4, 2009, Pages 488-492

  Firnhaber, Cynthia ^a   Viana, Raquel ^a   Reyneke, Anne ^a   Schultze, Doreen ^a   Malope, Babatyi ^a   Maskew, Mhairi ^a   Di Bisceglie, Adrian ^b   MacPhail, Patrick ^a   Sanne, Ian ^a   Kew, Michael ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Saint Louis University   (United States)

Author keywords

Co infection; Developing countries; HIV; Occult HBV; South Africa

Indexed keywords

ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SOUTH AFRICA; VIRUS LOAD;

ANTIBODIES, VIRAL; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; LIVER; PREVALENCE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; URBAN POPULATION; VIRAL LOAD;

EID: 67349242434     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.08.018     Document Type: Article

References (20)

1. Kramvis A., and Kew M.C. Epidemiology of hepatitis B virus and its genotypes in Africa, and the clinical associations of the genotypes. Hepatol Res 37 (2007) 9-19
2. Shisana O., Rehle T., Simbayi L., Parker W., Zuma K., Bhana A., et al. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2005 (2005), HSRC Press, Cape Town, South Africa
3. Hoffmann C., Charalambous S., Thio C., Martin D.J., Pemba L., Fielding K.L., et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21 (2007) 1301-1308
4. Lodenyo H., Schoub B., Ally R., Kairu S., and Segal I. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 77 (2000) 13-15
5. Firnhaber C., Reyneke A., and Schulze D. The prevalence of hepatitis B co-infection in a South African (SA) urban government HIV clinic. S Afr Med J 98 (2008) 541-544
6. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction?. J Hepatol 34 (2001) 471-473
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach; 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (accessed October 2008).
8. Torbenson M., and Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2 (2002) 479-486
9. Piroth L., Binquet C., Vergne M., Minello A., Livry C., Bour J.B., et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 36 (2002) 681-686
10. Shire N.J., Rouster S.D., Rajicic N., and Sherman K.E. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36 (2004) 869-875
11. Mphahlele M.J., Lukhwareni A., Burnett R.J., Moropeng L.M., and Ngobeni J.M. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35 (2006) 14-20
12. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. South Africa: Department of Health; 2003. Available at: http://www.info.gov.za/otherdocs/2003/aidsoperationalplan.pdf (accessed 20 January 2008).
13. Weinberger K.M., Wiedenmann E., Bohm S., and Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 85 (2000) 75-82
14. Tang Y., Li H., Roberto A., Warner D., and Yen-Lieberman B. Detection of hepatitis C virus by a user-developed reverse transcriptase-PCR and use of amplification products for subsequent genotyping. J Clin Virol 2 (2004) 148-152
15. Firnhaber C, Reyneke A, Azzoni L, Malope B, Jaffray I, van Amsterdam D, et al. HBV/HBC prevalence in an urban South African (SA) HIV clinic: implications for ARV care in the resource limited setting. Abstract 919. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California, USA, February 2007.
16. Lo Re III V., Frank I., Gross R., Dockter J., Linnen J.M., Giachetti C., et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44 (2007) 315-320
17. Filippini P., Coppola N., Pisapia R., Scolastico C., Marrocco C., Zaccariello A., et al. Impact of occult hepatitis B virus infection in HIV patients naïve for antiretroviral therapy. AIDS 20 (2006) 1253-1260
18. DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC: US Department of Health and Human Services; 2008. Available at: http://aidsinfo.nih.gov/guidelines (accessed October 2008).
19. Drake A., Mijch A., and Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B co-infection despite lamivudine therapy as part of HAART. Clin Infect Dis 39 (2004) 129-132
20. Hou J., Liu Z., and Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2 (2005) 50-57